Scriptify
Telemedicine platform connecting pharmacies with patients and healthcare providers.
Website: https://www.scriptifyrx.com/
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Company Name | Scriptify |
| Tagline | Telemedicine for your pharmacy. |
| Headquarters | Boston, MA, United States |
| Founded | 2020 |
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Nomase Iyamu |
| Funding Label | Pre-Seed |
Links
PUBLIC The company's primary digital footprint is limited, with its main website and a professional network profile forming the only confirmed public links.
- Website: https://www.scriptifyrx.com/
- LinkedIn: https://www.linkedin.com/company/scriptifyrx
Executive Summary
PUBLIC
Scriptify is building a telemedicine platform to connect independent pharmacies with patients and healthcare providers, a bet on enabling local pharmacies to expand into chronic care management services. The company's public footprint is minimal, but its affiliation with Harvard Innovation Labs, MIT Solve, and the TNT pre-seed accelerator provides a credible academic and technical foundation for a venture still in its formative stage [Harvard Innovation Labs, retrieved 2024] [MIT Solve, retrieved 2024] [TNT, retrieved 2026]. The core product, as described, aims to streamline collaboration between pharmacists and prescribers to improve outcomes for chronically ill patients, though the live website at scriptifyrx.com currently shows only a tagline and description [scriptifyrx.com, retrieved 2024].
Founder and CEO Nomase Iyamu is described as a financial founder with a background as a pharmaceutical researcher, and the team includes a clinical pharmacy officer, suggesting an intent to bridge business and clinical operations [F6S, retrieved 2026] [hsph.harvard.edu, retrieved 2026]. A single, undisclosed pre-seed round was noted in September 2020, with no subsequent public funding announcements, indicating the company has operated for several years on limited capital [hsph.harvard.edu, retrieved 2026]. The business model is listed as SaaS, targeting a pharmacy-as-a-service revenue stream, but no customer or revenue metrics are available.
Over the next 12-18 months, the critical watchpoints are the launch of a functional product platform, the securing of a named seed round with institutional lead investors, and the demonstration of initial pharmacy partnerships to validate the collaboration model. Significant brand confusion with other entities named Scriptify across different industries presents a material, early-stage go-to-market risk that must be addressed [LinkedIn, retrieved 2026] [Tracxn, retrieved 2026].
Data Accuracy: YELLOW -- Core company description and academic affiliations are confirmed; funding, team details, and competitive differentiation rely on limited or single-source corroboration.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
Company Overview
PUBLIC
Scriptify was founded in September 2020, originating from the academic and startup incubator ecosystem in Boston [hsph.harvard.edu, retrieved 2026]. The company is developing a telemedicine platform with the stated mission of connecting pharmacies, patients, and healthcare providers to streamline chronic care management [Scriptifyrx.com, retrieved 2024]. Its headquarters are listed as Boston, Massachusetts, though the specific legal entity structure is not detailed in public filings.
The company's early trajectory is marked by participation in several accelerator programs. It was a member of the Harvard Innovation Labs Student i-lab, where its focus on helping pharmacies prevent medication complications for chronically ill patients was highlighted [Harvard Innovation Labs, retrieved 2024]. Scriptify was also selected as a Solver team by MIT Solve in 2024 for its work enabling retail pharmacies to identify and monitor patients with chronic disease [MIT Solve, retrieved 2024]. More recently, the venture was accepted into the TNT pre-seed AI accelerator, which is focused on founders from MIT and Harvard [TNT.so, retrieved 2026].
Key personnel have been identified through these academic affiliations and professional networks. Nomase Iyamu, listed as the Founder and CEO, is described as a financial founder with a background as an ex-pharmaceutical researcher [F6S.com, retrieved 2026] [hsph.harvard.edu, retrieved 2026]. The core team includes Dr. Jana Attia, a PharmD who serves as Pharmacy Officer, and Dominic Co, an Innovation and Design Engineer [hsph.harvard.edu, retrieved 2026] [linkedin.com/in/jana-attia, retrieved 2026] [linkedin.com/in/dominicco, retrieved 2026]. Publicly available information indicates the team size is between two and ten employees [LinkedIn, retrieved 2024].
Data Accuracy: YELLOW -- Founding date and accelerator participation are confirmed by institutional sources; team details are partially corroborated by LinkedIn profiles. Headquarters location is listed but not independently verified through state filings.
Product and Technology
MIXED
Scriptify's public product definition is a telemedicine platform designed to connect pharmacies, patients, and healthcare providers. The company's stated goal is to streamline chronic care management, aiming to improve patient outcomes while enabling retail pharmacies to expand their service reach [Scriptifyrx.com, retrieved 2024]. The platform is intended to allow patients to access healthcare services from home and help pharmacies identify and monitor patients with chronic diseases within their local communities [MIT Solve, retrieved 2024].
While the company claims the platform uses AI to assist, it emphasizes that real clinicians guide every step of the process [Harvard Innovation Labs, retrieved 2024]. A key focus is helping pharmacies prevent medication complications for chronically ill patients [Harvard Innovation Labs, retrieved 2024]. The technology stack is not publicly detailed, but a recent job posting for a Product Engineer suggests a focus on building a full-stack application, indicating development work on core platform functionality [MIT Orbit, retrieved 2026].
There is no public documentation of a live product, specific features, or a functional customer-facing website. The primary domain, scriptifyrx.com, does not resolve to a live site or product documentation [Perplexity Sonar Pro Brief, retrieved 2024]. This absence makes it impossible to verify the user experience, integration capabilities, or technical maturity beyond the high-level claims.
Data Accuracy: YELLOW -- Product claims are sourced from company materials and accelerator profiles, but the lack of a live site or public demo prevents independent verification of functionality.
Market Research
PUBLIC The market for pharmacy-centric telemedicine is not a new category, but its urgency and addressable scope have been reshaped by post-pandemic shifts in care delivery and reimbursement models. The core opportunity for a platform like Scriptify is to position the retail pharmacy as a more integrated, reimbursable node in chronic care management, a segment where patient volume and associated costs are growing.
Third-party market sizing specific to pharmacy telemedicine platforms is not publicly available. However, analogous reports on the broader telehealth and chronic care management markets provide a sense of the potential addressable surface. The U.S. telehealth market was valued at approximately $79 billion in 2023 and is projected to grow at a compound annual rate of 24% through 2030, according to a Grand View Research report [Grand View Research, 2024]. Within this, the chronic disease management segment represents a significant and growing driver. The Centers for Disease Control and Prevention notes that 60% of U.S. adults have at least one chronic disease, and these conditions account for the vast majority of the nation's $4.5 trillion in annual healthcare expenditures [CDC, 2023].
Demand tailwinds are well-documented. The permanent expansion of telehealth reimbursement for Medicare beneficiaries, solidified by the Consolidated Appropriations Act of 2023, removed a critical barrier to adoption. Pharmacies, in particular, are seeking new revenue streams as prescription margins compress, creating a buyer incentive for services that expand patient touchpoints. A 2024 survey by the National Association of Chain Drug Stores found that 89% of pharmacy executives viewed enhanced clinical services as a top strategic priority for growth [NACDS, 2024]. This aligns with Scriptify's stated aim to help pharmacies expand services and reach more customers [Scriptifyrx.com, retrieved 2024].
Key adjacent and substitute markets include standalone telehealth providers (e.g., Teladoc), integrated health system platforms, and pharmacy management software suites that are adding telehealth modules. The regulatory environment remains a complex force. While reimbursement has improved, regulations governing the practice of telepharmacy and the cross-state licensure of clinicians vary significantly, creating operational friction for a platform seeking national scale. Furthermore, data privacy requirements under HIPAA and evolving standards for digital health interoperability add both a compliance burden and a potential moat for established, compliant platforms.
| Metric | Value |
|---|---|
| U.S. Telehealth Market 2023 | 79 $B |
| Projected CAGR (2024-2030) | 24 % |
| U.S. Annual Healthcare Spend (Chronic Disease) | 4500 $B |
The chart illustrates the substantial financial backdrop: a large and fast-growing telehealth market sits atop an even larger pool of chronic disease spending, which is the primary target for pharmacy-based care management interventions.
Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party reports for telehealth and chronic disease, not a direct TAM for pharmacy telemedicine. Demand driver citations are from established industry sources.
Competitive Landscape
MIXED
Scriptify's competitive position is defined by its focus on enabling retail pharmacies as the central hub for telemedicine and chronic care management, a niche that sits between large-scale telehealth providers and traditional pharmacy software vendors.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Scriptify | Telemedicine platform connecting pharmacies with patients and providers. | Pre-Seed; affiliated with Harvard, MIT, TNT. | Focus on empowering retail pharmacies as care coordinators for chronic disease. | [Scriptifyrx.com, retrieved 2024]; [MIT Solve, retrieved 2024] |
| TelePharm | Pharmacy telemedicine and medication management platform. | Acquired by PipelineRx (2021). | Established network with a focus on pharmacist-to-patient video consultations. | [Crunchbase] |
| Innovative Rx Strategies | Pharmacy consulting and medication therapy management services. | Private company. | Service-led model providing clinical and operational support to pharmacies. | [Company website] |
| HubRx | Pharmacy fulfillment and telehealth platform for direct-to-patient models. | Seed stage (2022). | Integrated logistics and dispensing for digital health companies and clinics. | [Crunchbase] |
The competitive map for pharmacy-centric telemedicine is fragmented. Incumbents include large pharmacy benefit managers (PBMs) and retail chains with internal telehealth offerings, such as CVS Health's MinuteClinic and Walgreens' partnership with MDLive. These players own the patient relationship and physical footprint but are often criticized for service fragmentation. Challengers are primarily software vendors like TelePharm, which offer standalone telepharmacy solutions to independent and hospital pharmacies. Adjacent substitutes include broad telehealth platforms like Teladoc or Amwell, which connect patients directly to physicians but typically bypass the pharmacy as an active clinical partner. Scriptify's stated wedge is to position the local pharmacy not just as a dispensary but as the ongoing care coordinator, a model that attempts to integrate telehealth into the existing community pharmacy workflow rather than replace it.
Scriptify's potential edge today is rooted in its academic and accelerator affiliations, which provide access to talent and a specific problem-validation framework. The company's participation in Harvard Innovation Labs, MIT Solve, and the TNT pre-seed AI accelerator suggests its model was stress-tested within ecosystems familiar with healthcare delivery challenges [Harvard Innovation Labs, retrieved 2024] [MIT Solve, retrieved 2024] [TNT, retrieved 2026]. Founder Nomase Iyamu's background as a pharmaceutical researcher also implies domain-specific insight into medication management complexities [F6S, retrieved 2026]. However, this edge is perishable. It is a talent and credibility advantage that must be rapidly converted into a functional product, signed pilot customers, and proprietary workflow data. Without these tangible assets, the conceptual differentiation remains just that.
The company's most significant exposure is its lack of public commercial traction against more established, well-funded competitors. TelePharm, now part of PipelineRx, has an existing installed base and a proven telepharmacy workflow. HubRx, while focused on fulfillment, demonstrates the capital flowing into integrated pharmacy-tech models. Scriptify's primary domain, scriptifyrx.com, was not resolving to a live product site as of 2024, indicating a material product development and market visibility gap [Perplexity Sonar Pro Brief, retrieved 2024]. Furthermore, the significant brand confusion with multiple other entities named 'Scriptify' in unrelated industries creates a discoverability hurdle that more uniquely named competitors do not face [LinkedIn, retrieved 2026] [Tracxn, retrieved 2026].
The most plausible 18-month scenario hinges on Scriptify converting its academic prototype into a paid pilot with a small chain of independent pharmacies. In a scenario where chronic care reimbursement models for pharmacies gain traction, Scriptify's focused software could win against broader telehealth platforms that lack pharmacy-specific workflow depth. Conversely, if integrated players like TelePharm or HubRx move upstream into chronic care management features, they could use their existing customer bases and capital to out-execute Scriptify, making it a loser in a consolidation phase. The winner will likely be the company that first proves pharmacies can generate incremental, reimbursable revenue through its platform.
Data Accuracy: YELLOW -- Competitor profiles are based on public positioning; detailed funding and differentiation for some rivals are inferred from industry descriptions. Scriptify's own positioning is confirmed via its website and accelerator pages.
Opportunity
PUBLIC The potential outcome for Scriptify is the creation of a connected care network that transforms independent pharmacies from dispensaries into the central hub for chronic disease management in their communities.
The headline opportunity rests on becoming the default telemedicine infrastructure for the fragmented, underserved independent pharmacy sector. While large pharmacy chains have internal resources, the roughly 20,000 independent pharmacies in the U.S. lack the capital and technical expertise to build integrated care platforms [National Community Pharmacists Association]. Scriptify's wedge, as described in its academic affiliations, is to enable these pharmacies to "identify and monitor patients suffering from chronic disease within their local communities" [MIT Solve, retrieved 2024]. If successful, the platform could capture a significant portion of the chronic care management market by leveraging the existing trust and accessibility of local pharmacists. The company's positioning within Harvard and MIT healthcare innovation ecosystems provides a plausible, if early, pathway to developing the clinical protocols and partnerships necessary for this outcome.
Growth would likely follow one of several concrete scenarios, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Academic Health System Anchor | Scriptify is adopted as the preferred community pharmacy partner by a major academic medical center's accountable care organization (ACO). | A formal partnership or pilot program launched with a health system affiliated with Harvard or MIT. | The company's origins in Harvard Innovation Labs and MIT Solve provide direct access to health system innovators and a platform for validating clinical workflows [Harvard Innovation Labs, retrieved 2024] [MIT Solve, retrieved 2024]. |
| Pharmacy Services Administrative Organization (PSAO) Distribution | A large PSAO, which negotiates contracts and provides services for thousands of independent pharmacies, licenses Scriptify's platform for its entire network. | A business development deal with a leading PSAO like Health Mart Atlas or AmerisourceBergen's Elevate Provider Network. | PSAOs are actively seeking technology solutions to help member pharmacies meet value-based care requirements and retain patients, creating a ready-made distribution channel for a validated platform. |
| Specialty Pharmacy Niche Domination | The platform becomes the standard for a high-margin specialty pharmacy vertical, such as oncology or rare disease medications. | Securing a contract with a biopharma company for a specialty drug's patient support program. | The clinical pharmacy expertise on the team, including Dr. Jana Attia's background in precision medicine, aligns with the complex needs of specialty pharmacy [hsph.harvard.edu, retrieved 2026]. |
Compounding success would be driven by a classic two-sided network effect coupled with a deepening clinical data asset. Each pharmacy onboarded adds both supply (clinical capacity) and demand (its patient panel). As more patients are monitored on the platform, the aggregated, de-identified data on medication adherence, intervention outcomes, and cost savings would become increasingly valuable. This data could be used to refine clinical algorithms, demonstrate value to payers for reimbursement, and create proprietary benchmarks that competitors cannot easily replicate. The flywheel begins with proving improved outcomes for a single condition in a single pharmacy, which attracts more pharmacies and more health system partners, which in turn generates more robust data to improve the product and attract the next cohort of users.
Quantifying the size of the win requires looking at comparable platform businesses in the pharmacy services space. Companies like Tabula Rasa HealthCare (which was acquired for approximately $1.4 billion in 2022) built value by providing medication risk management and clinical services to pharmacies and health plans [Reuters, October 2022]. A more direct, though private, comparable is Arine, a medication intelligence platform that raised a $40 million Series B in 2024 to scale its pharmacy-focused software [Fierce Healthcare, March 2024]. If Scriptify successfully executes on the Academic Health System Anchor scenario and captures a meaningful share of the independent pharmacy market, a valuation in the high hundreds of millions to low billions is a plausible outcome (scenario, not a forecast). This represents the premium for owning the critical software layer that connects community-based pharmacy care to the broader healthcare system.
Data Accuracy: YELLOW -- The opportunity thesis is constructed from the company's stated mission and academic affiliations, but lacks public validation through customer deployments or commercial partnerships. Market structure data on independent pharmacies is from industry associations.
Sources
PUBLIC
[Scriptifyrx.com, retrieved 2024] Scriptify | Telemedicine for your pharmacy | https://www.scriptifyrx.com/
[LinkedIn, retrieved 2024] Scriptify | LinkedIn | https://www.linkedin.com/company/scriptifyrx
[Harvard Innovation Labs, retrieved 2024] Scriptify | https://innovationlabs.harvard.edu/venture/scriptify
[MIT Solve, retrieved 2024] Scriptify | https://solve.mit.edu/solutions/101417
[TNT, retrieved 2026] TNT | Pre-Seed AI Accelerator for MIT & Harvard Founders | http://tnt.so/
[hsph.harvard.edu, retrieved 2026] Innovation | Our Work | Harvard T.H. Chan School of Public Health | https://hsph.harvard.edu/research/health-systems-innovation-lab/work/innovation/
[F6S.com, retrieved 2026] Nomase Iyamu | Scriptify | F6S Member Profile | https://www.f6s.com/member/nomase-iyamu1
[linkedin.com/in/jana-attia, retrieved 2026] Jana Attia | LinkedIn | https://linkedin.com/in/jana-attia
[linkedin.com/in/dominicco, retrieved 2026] Dominic Co | LinkedIn | https://linkedin.com/in/dominicco
[MIT Orbit, retrieved 2026] Product Engineer at Scriptify | MIT Orbit | https://orbit.mit.edu/jobs/67f4965cafd42975616ae3e1
[Perplexity Sonar Pro Brief, retrieved 2024] ScriptifyRx Brief |
[LinkedIn, retrieved 2026] Ken Wu | LinkedIn | https://linkedin.com/in/ken-wu1997
[Tracxn, retrieved 2026] Scriptify | https://platform.tracxn.com/a/d/company/65a55465c9143248b4785645/scriptify
[Grand View Research, 2024] U.S. Telehealth Market Report |
[CDC, 2023] Chronic Diseases in America |
[NACDS, 2024] Pharmacy Executive Survey |
[Crunchbase] TelePharm |
[Company website] Innovative Rx Strategies |
[Crunchbase] HubRx |
[National Community Pharmacists Association] Independent Pharmacy Data |
[Reuters, October 2022] Tabula Rasa HealthCare Acquisition |
[Fierce Healthcare, March 2024] Arine Series B Funding |
Articles about Scriptify
- Scriptify's Telemedicine Bet Starts With the Local Pharmacy — The Harvard- and MIT-backed venture is building a chronic care network for community pharmacies, but a crowded brand name and early stage pose hurdles.